Kristopher Lybarger, DO
Gynecologic Oncology · Kansas City, MONPI 1013172022
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Davol Inc. at 46.2% of the total. Reporting peaked in 2023 at $208,910 and has fallen 61.8% since, to $79,756 in 2025. Among gynecologic oncology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 935 payments — averaging $794.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$343K
- GSK$177K
- Tesaro, Inc.$95K
- Clovis Oncology, Inc.$41K
- Seagen Inc.$24K
- Genmab U.S., Inc.$22K
- plus $41K from 30 others
Across 260 payments — averaging $4056.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$284K
- Karyopharm Therapeutics Inc.$244K
- GSK$238K
- Incyte Corporation$127K
- Genmab U.S., Inc.$84K
- Eli Lilly$50K
- plus $29K from 4 others
What the payments were for
- Consulting fees$147,95720%
- Speaking & faculty fees$410,52855%
- Travel & lodging$160,01622%
- Food & beverage$20,9433%
- Education$3,4790%
- Gifts$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 325 | $342,921 |
| GSK | 123 | $176,977 |
| Tesaro, Inc. | 143 | $94,522 |
| Clovis Oncology, Inc. | 39 | $40,965 |
| Seagen Inc. | 26 | $24,462 |
| Genmab U.S., Inc. | 27 | $21,695 |
| Myriad Genetic Laboratories, Inc. | 17 | $9,227 |
| Medical Device Business Services, Inc. | 11 | $8,254 |
| Immunogen, Inc. | 21 | $6,552 |
| Intuitive Surgical | 24 | $6,454 |
| AstraZeneca | 18 | $2,711 |
| Johnson & Johnson(3 entities) | 35 | $2,273 |
| BD | 12 | $1,185 |
| Merck | 52 | $1,127 |
| Karyopharm Therapeutics Inc. | 4 | $1,043 |
| Pfizer | 2 | $918 |
| AbbVie | 19 | $595 |
| Dysis Medical, Inc. | 4 | $268 |
| Eisai Inc. | 12 | $264 |
| Genentech, Inc. | 1 | $147 |
| Integra Lifesciences Corporation | 2 | $52 |
| Olympus America Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Verastem, Inc. | 1 | $33 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Teleflex LLC | 1 | $23 |
| Gilead | 1 | $22 |
| Incyte Corporation | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Novartis | 1 | $18 |
| Sanofi | 1 | $18 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Axonics, Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$160,108
- JEMPERLI$105,637
- ARISTA AH FLEXITIP$61,054
- TIVDAK$45,658
- Rubraca$40,506
- ARISTA$11,089
- SURGIFLO Hemostatic Matrix$8,080
- myChoice CDx$6,656
- Elahere$6,194
- Da Vinci Surgical System$5,906
- myRisk$2,100
- XPOVIO$1,023
- PROGEL$750
- Phasix Mesh$347
- DYSIS V3 DIGITAL COLPOSCOPE$203
- RiskScore$150
- KEYTRUDA$120
- Enseal$115
- ECHELON ENDOPATH$115
- Echelon Circular$115
How this compares
$742,957 in reported general payments places this provider in the 95th percentile of 38 gynecologic oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 12 | $226,562 |
| Megestrol Acetate | 21 | $993 |
| Letrozole | 41 | $916 |
| Gabapentin | 83 | $439 |
| Tramadol Hcl | 84 | $352 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $314 |
| Ibuprofen | 55 | $232 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 18 | $216 |
| Methylprednisolone | 14 | $61 |
| Lorazepam | 19 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $2,711 | $226,56212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 gynecologic oncology providers in Missouri.
Other gynecologic oncology in Kansas City
- Jason KnightKansas City$1K
- Verda HicksKansas City$1K
- Susan Duyar-AyerdiKansas City$550
- Michelle RowlandKansas City$464
- Nora BadinerKansas City$152
- John WeedKansas City$86
- Premal ThakerSaint Louis$287K
- Matthew PowellSaint Louis$162K
- Sara CrowderColumbia$69K
- David MutchSaint Louis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.